Wednesday , October 18 2017
Home / 2015 / October

Monthly Archives: October 2015

Ultragenyx and Arcturus Enter Potential $1.57 Billion RNA Collaboration

NOVATO, Calif., Oct. 29, 2015 /PRNewswire/ — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Arcturus Therapeutics, Inc., a leading RNA medicines company, today announced that they have entered into a research collaboration and license agreement to discover …

Read More »

Gilead Submits NDA for its Investigational Hep C Combo

FOSTER CITY, Calif.–(BUSINESS WIRE)–Oct. 28, 2015– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi® in December 2013, and …

Read More »

Understanding Immuno-Oncology

The field of immuno-oncology combines an understanding of how the body’s own defenses (e.g., the immune system) can be harnessed in the fight against cancer. Cancer cells, although different than the body’s healthy cells, find ways to disguise themselves so that the immune system doesn’t recognize them as non-self and …

Read More »

Igenica Partners with MedImmune to Research Anti-SAIL ADCs

BURLINGAME, Calif.–(BUSINESS WIRE)–Igenica Biotherapeutics, Inc., a company focused on the discovery and development of innovative antibody-based therapies for the treatment of cancer, announced today that it has entered into an oncology research agreement with MedImmune, the global biologics research and development arm of AstraZeneca (NYSE: AZN). Igenica and MedImmune will …

Read More »

Boehringer Ingelheim’s Biosimilar Candidate Demonstrated Bioequivalence to Adalimumab in Clinical Trial

RIDGEFIELD, Conn. and ORLANDO, Fla., Oct. 28, 2015 /PRNewswire/ — Boehringer Ingelheim today announced results from a Phase I study (NCT02045979) of its biosimilar candidate (BI695501) for adalimumab (AbbVie’s Humira®), that demonstrated pharmacokinetic bioequivalence with both the U.S.-licensed and EU-approved reference products.  These data were presented in a poster at …

Read More »

Natera’s mmPCR Technology Successfully Identified breast Cancer in Study

SAN CARLOS, Calif., Oct. 28, 2015 /PRNewswire/ — Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced a study published in the October 2015 issue of Translational Oncology showing that Natera’s massively multiplexed PCR (mmPCR) technology and proprietary analytic methodologies can detect …

Read More »

FDA Approves Amgen’s Imlygic as First Oncolytic Viral Therapy in the US

THOUSAND OAKS, Calif., Oct. 27, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for IMLYGIC™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in …

Read More »